Logo
x

Search

Subscribe Now

Axsome

Axsome Reports (SHARP) Study Results of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Reports (SHARP) Study Results of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Obstructive Sleep A...

  • October 3, 2022
Axsome’s Auvelity Receives the US FDA’s Approval for the Treatment of Major Depressive Disorder

Axsome’s Auvelity Receives the US FDA’s Approval for the Treatment of Major Depressive Disorder

  • August 19, 2022
Axsome Publishes Results of AXS-05 (dextromethorphan-bupropion) in P-III (GEMINI) Trial for Major Depressive Disorder in The Journal of Clinical Psychiatry

Axsome Publishes Results of AXS-05 (dextromethorphan-bupropion) in P-III (GEMINI) Trial for Major Depressive Disorder in The Journ...

  • June 2, 2022
Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness

Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness

  • March 28, 2022
Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

  • March 11, 2021
PharmaShots Weekly Snapshot (January 13-17, 2020)

PharmaShots Weekly Snapshot (January 13-17, 2020)

  • January 20, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.